DCTH Delcath stock news
On September 18, 2026, Delcath Systems Inc. (Nasdaq: DCTH) announced the activation of Stanford Medicine as its 23rd commercial treatment center for the HEPZATO KIT. This expansion into a premier academic medical center is a significant milestone in the company's U.S. commercial rollout, supporting its strategic objective to have 30 active treatment sites operational by the end of 2026. Management also confirmed its participation in the Cantor Global Healthcare Conference on September 28, 2026, and highlighted that the permanent J--code (J7402) for the HEPZATO KIT will officially become effective on October 1, 2026, which is expected to significantly reduce administrative barriers and accelerate patient treatment volumes.